-
Je něco špatně v tomto záznamu ?
Challenges of Huntington's disease and quest for therapeutic biomarkers
E. Kotrcova, K. Jarkovska, I. Valekova, M. Zizkova, J. Motlik, SJ. Gadher, H. Kovarova,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
25290828
DOI
10.1002/prca.201400073
Knihovny.cz E-zdroje
- MeSH
- biologické markery metabolismus MeSH
- Huntingtonova nemoc metabolismus terapie MeSH
- lidé MeSH
- proteiny nervové tkáně metabolismus MeSH
- proteom analýza MeSH
- proteomika metody MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Huntington's disease (HD) is the most common inherited neurodegenerative disorder among polyglutamine (polyQ) diseases caused by cytosine-adenine-guanine repeat expansion in exon 1 of the huntingtin gene whose translation results in polyQ stretch in the N-terminus of the huntingtin protein (HD protein). This mutation significantly affects huntingtin conformation, proteolysis, PTMs, as well as its ability to bind interacting proteins. As a consequence, a variety of cellular mechanisms such as transcription, mitochondrial energy metabolism, axonal transport, neuronal vulnerability to oxidative stress, neurotransmission, and immune response are altered and involved in the pathogenesis of HD. Promising candidate molecular biomarkers of HD have emerged from proteomic studies. Recent analyses focused on HD protein itself, its PTM, and interacting proteins, which are of great importance for disease course. Furthermore, brain, body fluids, and immune system are intensively studied in order to search for additional proteins with a view to their use as a biomarker(s) or set of biomarkers in clinical trials in HD translational research.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031803
- 003
- CZ-PrNML
- 005
- 20151014113639.0
- 007
- ta
- 008
- 151005s2015 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/prca.201400073 $2 doi
- 035 __
- $a (PubMed)25290828
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Kotrcova, Eva $u Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Libechov, Czech Republic; Research Center PIGMOD, Libechov, Czech Republic.
- 245 10
- $a Challenges of Huntington's disease and quest for therapeutic biomarkers / $c E. Kotrcova, K. Jarkovska, I. Valekova, M. Zizkova, J. Motlik, SJ. Gadher, H. Kovarova,
- 520 9_
- $a Huntington's disease (HD) is the most common inherited neurodegenerative disorder among polyglutamine (polyQ) diseases caused by cytosine-adenine-guanine repeat expansion in exon 1 of the huntingtin gene whose translation results in polyQ stretch in the N-terminus of the huntingtin protein (HD protein). This mutation significantly affects huntingtin conformation, proteolysis, PTMs, as well as its ability to bind interacting proteins. As a consequence, a variety of cellular mechanisms such as transcription, mitochondrial energy metabolism, axonal transport, neuronal vulnerability to oxidative stress, neurotransmission, and immune response are altered and involved in the pathogenesis of HD. Promising candidate molecular biomarkers of HD have emerged from proteomic studies. Recent analyses focused on HD protein itself, its PTM, and interacting proteins, which are of great importance for disease course. Furthermore, brain, body fluids, and immune system are intensively studied in order to search for additional proteins with a view to their use as a biomarker(s) or set of biomarkers in clinical trials in HD translational research.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Huntingtonova nemoc $x metabolismus $x terapie $7 D006816
- 650 _2
- $a proteiny nervové tkáně $x metabolismus $7 D009419
- 650 _2
- $a proteom $x analýza $7 D020543
- 650 _2
- $a proteomika $x metody $7 D040901
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Jarkovska, Karla
- 700 1_
- $a Valekova, Ivona
- 700 1_
- $a Zizkova, Martina
- 700 1_
- $a Motlik, Jan
- 700 1_
- $a Gadher, Suresh Jivan
- 700 1_
- $a Kovarova, Hana
- 773 0_
- $w MED00157628 $t Proteomics. Clinical applications. Clinical applications $x 1862-8354 $g Roč. 9, č. 1-2 (2015), s. 147-58
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25290828 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151014113829 $b ABA008
- 999 __
- $a ok $b bmc $g 1092679 $s 914929
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 9 $c 1-2 $d 147-58 $e 20141102 $i 1862-8354 $m Proteomics. Clinical applications $n Proteomics Clin Appl $x MED00157628 $o Clinical applications
- LZP __
- $a Pubmed-20151005